NPPNY News and Press, Nippon Shinyaku Co Ltd ADR

2025-11-04 14:38:13 ET Thesis Read the full article on Seeking Alpha For further details see: Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?

2025-03-26 12:31:18 ET Summary Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, with potential for the EV to turn negative once ...

2025-01-02 09:57:37 ET More on Capricor Therapeutics, Nippon Shinyaku Co., Ltd., etc. Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission Capricor Therapeutics, ...